Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.

Antineoplastic Agents / chemical synthesis Cell Line, Tumor Cell Proliferation / drug effects Dose-Response Relationship, Drug Drug Screening Assays, Antitumor ErbB Receptors / antagonists & inhibitors Humans Molecular Structure Protein Kinase Inhibitors / chemical synthesis Quinazolines / chemical synthesis Structure-Activity Relationship Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors
Angiogenesis Microtubule targeting agents Multi-target inhibitors Quinazolines Receptor tyrosine kinase

Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 04 2021
Historique:
received: 11 11 2020
revised: 28 01 2021
accepted: 01 02 2021
pubmed: 2 3 2021
medline: 16 9 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

The efficacy of quinazoline-based antiglioma agents has been attributed to their effects on microtubule dynamics.

Identifiants

DOI: 10.1016/j.bmc.2021.116061 PMID: 33647840 PMC: PMC7995636
pubmed: 33647840
pii: S0968-0896(21)00069-9
doi: 10.1016/j.bmc.2021.116061
pmc: PMC7995636
mid: NIHMS1680522
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Protein Kinase Inhibitors 0
Quinazolines 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
KDR protein, human EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

116061

Subventions

Organisme : NCI NIH HHS
ID : R01 CA142868
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

ACS Med Chem Lett. 2014 Feb 27;5(5):480-4
pubmed: 24900865
J Clin Oncol. 2013 Jun 10;31(17):2205-18
pubmed: 23669226
J Med Chem. 1995 Sep 1;38(18):3482-7
pubmed: 7658435
Cancer. 2016 Apr 1;122(7):1108-15
pubmed: 27000445
J Antibiot (Tokyo). 2017 Nov;70(11):1033-1042
pubmed: 28874848
Radiother Oncol. 2013 Sep;108(3):370-7
pubmed: 23830194
Bioorg Med Chem. 2014 Jul 15;22(14):3753-72
pubmed: 24890652
J Thorac Oncol. 2014 Feb;9(2):214-21
pubmed: 24419419
J Struct Biol. 2015 Dec;192(3):539-544
pubmed: 26522274
Bioorg Med Chem. 2015 Sep 1;23(17):5740-7
pubmed: 26242242
Cancer. 2015 May 1;121(9):1405-13
pubmed: 25641662
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3423-3430
pubmed: 28610978
Int J Mol Sci. 2018 Nov 06;19(11):
pubmed: 30404198
J Med Chem. 2019 Oct 24;62(20):8881-8914
pubmed: 31082225
Nat Rev Mol Cell Biol. 2015 Dec;16(12):711-26
pubmed: 26562752
PLoS One. 2015 Aug 14;10(8):e0134731
pubmed: 26275293
Int J Mol Sci. 2017 Aug 09;18(8):
pubmed: 28792473
Mol Pharmacol. 1998 Jan;53(1):62-76
pubmed: 9443933
Org Lett. 2004 Sep 30;6(20):3477-80
pubmed: 15387527
J Med Chem. 2012 Mar 8;55(5):2353-66
pubmed: 22309223
Cancer Res. 2008 Nov 1;68(21):8881-8
pubmed: 18974132
Cancer Sci. 2011 Aug;102(8):1545-52
pubmed: 21631643
J Org Chem. 2011 May 20;76(10):4149-53
pubmed: 21469735
Br J Pharmacol. 2013 Oct;170(4):712-29
pubmed: 23962094
Cancer. 2015 Nov 15;121(22):4007-15
pubmed: 26264378
Biochemistry. 1984 Aug 28;23(18):4173-84
pubmed: 6487596
J Med Chem. 2015 Jan 22;58(2):994-1004
pubmed: 25522110
Angiogenesis. 2017 May;20(2):185-204
pubmed: 28361267
J Mol Biol. 2014 Apr 17;426(8):1848-60
pubmed: 24530796
J Cell Mol Med. 2016 Dec;20(12):2231-2240
pubmed: 27605177
Mol Cancer Ther. 2013 Feb;12(2):131-40
pubmed: 23270924
Cancer Invest. 2011 May;29(4):325-37
pubmed: 21469981
J Org Chem. 2004 Oct 1;69(20):6572-89
pubmed: 15387579
J Med Chem. 2008 Aug 14;51(15):4771-9
pubmed: 18651728
Bioorg Med Chem. 2014 Sep 15;22(18):5050-9
pubmed: 24650703
Mol Cancer. 2019 Mar 30;18(1):60
pubmed: 30925919
Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18281-9
pubmed: 22988103
Annu Rev Physiol. 2019 Feb 10;81:505-534
pubmed: 30742782
Crit Rev Oncol Hematol. 2018 Nov;131:46-52
pubmed: 30293705
Front Immunol. 2019 Jan 14;9:3107
pubmed: 30692993
J Cancer Res Clin Oncol. 2012 Nov;138(11):1879-90
pubmed: 22736027
Transl Cancer Res. 2016 Jun;5(Suppl 1):S54-S60
pubmed: 30680290
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
Invest New Drugs. 2015 Dec;33(6):1248-56
pubmed: 26453566
Trends Cell Biol. 2018 Oct;28(10):776-792
pubmed: 29871823
Oncol Rep. 2010 Oct;24(4):1049-58
pubmed: 20811688
J Biol Chem. 2002 Nov 29;277(48):46265-72
pubmed: 12196540
Eur J Med Chem. 2013 Sep;67:196-207
pubmed: 23867604
Clin Genitourin Cancer. 2015 Dec;13(6):540-7.e1-7
pubmed: 26320662
Cancer Discov. 2014 Jan;4(1):31-41
pubmed: 24356098
Trends Cancer. 2018 Apr;4(4):258-259
pubmed: 29606306
J Med Chem. 2009 Apr 23;52(8):2341-51
pubmed: 19296653
Head Neck. 2015 Feb;37(2):182-7
pubmed: 24346857
Nat Rev Drug Discov. 2016 Jun;15(6):385-403
pubmed: 26775688
Neuro Oncol. 2012 Dec;14(12):1519-26
pubmed: 23099652
J Nat Prod. 2019 Mar 22;82(3):680-685
pubmed: 30835122
J Med Chem. 2011 Sep 8;54(17):6151-5
pubmed: 21786793
Chem Biol. 1999 Feb;6(2):71-83
pubmed: 10021420
J Med Chem. 1996 Jan 5;39(1):267-76
pubmed: 8568816
Bioorg Med Chem. 2017 Jan 15;25(2):545-556
pubmed: 27894589

Auteurs

Shruti Choudhary (S)

Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, United States.

Arpit Doshi (A)

Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, United States.

Lerin Luckett-Chastain (L)

College of Pharmacy, University of Oklahoma Health Science Center, 1110 North Stonewall, Oklahoma City, OK 73117, United States.

Michael Ihnat (M)

College of Pharmacy, University of Oklahoma Health Science Center, 1110 North Stonewall, Oklahoma City, OK 73117, United States.

Ernest Hamel (E)

Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.

Susan L Mooberry (SL)

Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States.

Aleem Gangjee (A)

Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, United States. Electronic address: gangjee@duq.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Potential of substituted quinazolines to...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Potential of substituted quinazolines to...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Potential of substituted quinazolines to...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › Potential of substituted quinazolines to...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de criblage d'agents antitumoraux › Potential of substituted quinazolines to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › Potential of substituted quinazolines to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Potential of substituted quinazolines to...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Potential of substituted quinazolines to...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Potential of substituted quinazolines to...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinazolines › Potential of substituted quinazolines to...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Potential of substituted quinazolines to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs aux facteurs de croissance endothéliale vasculaire › Récepteur-2 au facteur croissance endothéliale vasculaire › Potential of substituted quinazolines to...